Your browser is no longer supported. Please, upgrade your browser.
Settings
SCMP Sucampo Pharmaceuticals, Inc. daily Stock Chart
SCMP [NASD]
Sucampo Pharmaceuticals, Inc.
Index- P/E39.60 EPS (ttm)0.30 Insider Own54.19% Shs Outstand45.84M Perf Week2.16%
Market Cap540.91M Forward P/E7.02 EPS next Y1.68 Insider Trans-1.47% Shs Float26.11M Perf Month3.06%
Income13.40M PEG2.83 EPS next Q0.48 Inst Own43.30% Short Float26.47% Perf Quarter-25.55%
Sales212.40M P/S2.55 EPS this Y147.70% Inst Trans3.72% Short Ratio6.44 Perf Half Y3.33%
Book/sh3.38 P/B3.49 EPS next Y38.16% ROA2.90% Target Price17.33 Perf Year-9.58%
Cash/sh- P/C- EPS next 5Y14.00% ROE11.70% 52W Range9.59 - 17.55 Perf YTD-12.92%
Dividend- P/FCF24.70 EPS past 5Y67.30% ROI10.10% 52W High-32.76% Beta1.37
Dividend %- Quick Ratio3.20 Sales past 5Y19.90% Gross Margin63.60% 52W Low23.04% ATR0.49
Employees159 Current Ratio3.60 Sales Q/Q73.40% Oper. Margin15.10% RSI (14)43.37 Volatility3.60% 4.27%
OptionableYes Debt/Eq1.51 EPS Q/Q19.20% Profit Margin6.30% Rel Volume0.35 Prev Close11.75
ShortableYes LT Debt/Eq1.36 EarningsMar 07 BMO Payout0.00% Avg Volume1.07M Price11.80
Recom2.30 SMA203.99% SMA50-8.43% SMA200-4.64% Volume379,678 Change0.43%
Dec-22-16Upgrade Mizuho Neutral → Buy $16
Nov-15-16Reiterated Maxim Group Buy $17 → $19
Nov-14-16Reiterated Mizuho Neutral $13 → $16
Sep-07-16Initiated Northland Capital Outperform
Aug-04-16Downgrade Mizuho Buy → Neutral $13
Aug-01-16Reiterated Maxim Group Buy $26 → $17
May-05-16Upgrade WallachBeth Hold → Buy $16
Apr-20-16Upgrade Mizuho Neutral → Buy $14
Mar-10-16Reiterated WallachBeth Hold $27 → $16
Mar-09-16Reiterated Maxim Group Buy $25 → $26
Jan-15-16Reiterated Mizuho Neutral $19 → $14
Nov-20-15Initiated Jefferies Hold $19
Nov-13-15Reiterated Mizuho Neutral $22 → $19
Oct-29-15Resumed ROTH Capital Buy $29
Oct-09-15Initiated Mizuho Neutral
Sep-03-15Initiated Leerink Partners Mkt Perform
Aug-27-15Reiterated WallachBeth Hold $24 → $27
Aug-27-15Reiterated H.C. Wainwright Buy $31 → $36
Aug-24-15Initiated H.C. Wainwright Buy $31
Aug-06-15Reiterated WallachBeth Hold $19 → $24
Feb-17-17 05:41PM  Sucampo Pharmaceuticals Set to Join S&P SmallCap 600 PR Newswire
02:04PM  Shire (SHPG) Beats on Q4 Earnings, Sales; Gives Upbeat View
Feb-16-17 04:25PM  Zoetis (ZTS) Beats Q4 Earnings Estimates, Lowers Outlook
Feb-09-17 10:36AM  Glaxo (GSK) Beats on Q4 Earnings, Posts Dismal '17 View
06:30AM  Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 Leerink Global Healthcare Conference GlobeNewswire
Feb-07-17 10:56AM  Mallinckrodt (MNK) Tops on Earnings in Transition Quarter
Feb-06-17 08:19AM  Portola, HealthCare Royalty Partners Ink $150 Million Deal
Feb-03-17 08:06AM  AMAG Down Despite Positive Data on Makena Auto-Injector
Feb-02-17 09:49AM  Novartis (NVS) Votubia Gets EU Approval for Label Expansion
07:21AM  Catabasis Hits 52-Week Low on Poor DMD Drug Study Data
Jan-31-17 10:45AM  Mylan (MYL) Gets Favorable Verdict for Copaxone in the US
Jan-30-17 04:19PM  Endo (ENDP) Restructures Branded Pharmaceutical Unit (revised)
10:20AM  Celgene (CELG) Gets Favorable CHMP Opinion for Revlimid
Jan-27-17 02:42PM  AbbVie (ABBV) Q4 Earnings Meet Estimates, Revenues Lag
09:05AM  Endo (ENDP) Restructures its Branded Pharmaceutical Unit
Jan-26-17 03:29PM  Celgene (CELG) Misses on Earnings & Revenues, Keeps View
Jan-23-17 05:26PM  Gilead (GILD) HCV Therapy Application Validated in Europe
05:22PM  Bristol-Myers Settles Litigation with Merck for Keytruda
08:28AM  Prima Biomed Initiates Randomized Study for Breast Cancer
Jan-19-17 09:04AM  Apricus (APRI) Stock Gains on Vitaros' Approval in Mexico
Jan-18-17 08:29AM  Agenus, NCI Ink Deal to Evaluate Prophage-Keytruda Combo
08:26AM  Benitec Stock Up on Orphan Drug Status for BB-301 in EU
Jan-17-17 09:30AM  Zacks.com featured highlights: Glaukos, Daqo New Energy, Calavo Growers and Sucampo Pharmaceuticals -5.60%
08:28AM  Key FDA Events to Watch Out for in Q1
Jan-16-17 08:16AM  4 Profitable Stocks with Amazingly High Returns
08:09AM  5 Top Ranked Stocks with Upgraded Broker Ratings to Buy Now
Jan-13-17 09:55AM  Coherus Offers Positive Phase III Data on Humira Biosimilar
Jan-12-17 04:19PM  TherapeuticsMD's Rejoice Study Data Published in Journal
08:43AM  Merck KGaA, Vertex Announce Tie-Up for Oncology Programs
Jan-11-17 04:42PM  Valeant Streamlines Portfolio with Skincare Brands Sale
09:30AM  The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Insulet, Western Refining, PennyMac Mortgage Investment Trust and Extended Stay America
08:27AM  Novo Nordisk (NVO) Fiasp Gets EU Nod for Diabetes in Adults
Jan-10-17 06:03PM  5 Underperformers of 2016: Turnaround Story in 2017?
09:30AM  Zacks.com featured highlights: NVIDIA, Sucampo Pharmaceuticals, Calavo Growers, Tucows and E*TRADE Financial
Jan-09-17 08:23AM  Go Driehaus Way: 5 Momentum Picks
07:32AM  SUCAMPO PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jan-06-17 10:18AM  Top Ranked Growth Stocks to Buy for January 6th
Jan-04-17 09:30AM  The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Dr. Reddy's Laboratories, BioMarin Pharmaceutical and Repligen
08:51AM  Why Sucampo Pharmaceuticals (SCMP)Could Be an Impressive Growth Stock
Jan-03-17 08:32AM  3 Overlooked Drug Stocks to Watch Out for in 2017
Dec-29-16 09:30AM  Zacks.com featured highlights: Calavo Growers, Cytokinetics, Sucampo Pharmaceuticals, State National and CryoLife
Dec-28-16 07:37AM  5 Profitable Stocks to Buy for Great Returns
Dec-27-16 04:17PM  SUCAMPO PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fi
09:07AM  Portola Betrixaban Accepted for Review in U.S. & EU, Stock Up
07:11AM  4 Top Stocks with Earnings Acceleration to Buy in 2017
Dec-23-16 11:22AM  Trump, Interest Rates And Biotech Investing In 2017 at Forbes
08:35AM  Ironwood, Allergan Report Positive Linzess IBS-C Study Data
Dec-22-16 01:19PM  Sucampo Pharmaceuticals, Inc. (SCMP) Announces Its New Debt Offering Of Convertible Notes at Insider Monkey
09:43AM  Sucampo Pharmaceuticals, Inc. Value Analysis (NASDAQ:SCMP) : December 22, 2016
06:14AM  Sucampo Pharma upgraded by Mizuho
Dec-21-16 04:15PM  Stock Indexes Calm; Southwestern Energy Up 6%
07:32AM  Sucampo Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SCMP-US : December 21, 2016
02:00AM  Sucampo Announces Pricing of $260.0 Million 3.25% Convertible Senior Notes due 2021 GlobeNewswire
Dec-20-16 05:40PM  Why NeoPhotonics, Sucampo Pharmaceuticals, and Worthington Industries Slumped Today at Motley Fool -20.48%
02:50PM  Here's Why Sucampo Pharmaceuticals Is Down Over 20% Today at Motley Fool
01:36PM  Dow Flirts With 20,000 As Caterpillar, Goldman Sachs, Nike Score Gains
Dec-19-16 04:06PM  SUCAMPO PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +6.03%
04:01PM  Sucampo Announces Proposed Convertible Senior Note Offering GlobeNewswire
01:47PM  Big-Cap Tech Names, Biotechs, Oils Lifting Market
08:47AM  Agios Stops Development of PKR Activator AG-519, Stock Falls
Dec-16-16 08:17AM  Roche (RHHBY) to Terminate Pacifica Bioscience Agreement
Dec-15-16 06:27AM  athenahealth (ATHN) Reaffirms 2016 View, Guides for 2017
Dec-14-16 09:17AM  Envision Healthcare Acquires Desert Mountain Consultants
08:09AM  Eli Lilly (LLY) to Offer Discount on Insulin from January
07:58AM  Kite Pharma Enters into Partnership with Vitruvian Networks
07:39AM  Proteon Slips to 52-Week Low on Kidney Disease Study Data
Dec-13-16 02:04PM  Top 10 Stocks Under $20
11:10AM  Stocks Stay Higher Ahead Of Fed; Dow Starts Eyeing 20,000
Dec-08-16 10:08AM  Pfizer (PFE) Fined for Price Hike of Anti-Epilepsy Drug in UK
09:30AM  Zacks.com featured highlights: Lancaster Colony, Sucampo Pharmaceuticals, Citrix Systems, VMware and Sanchez Energy
09:00AM  Mylan (MYL) Stock Falls on Restructuring Plans, Layoffs
Dec-07-16 10:01AM  5 Stocks to Buy for Remarkable Earnings Growth in 2017 -5.51%
09:30AM  The Zacks Analyst Blog Highlights: Health Insurance Innovations, Aegean Marine Petroleum Network, KVH Industries, Sucampo Pharmaceuticals and Willdan Group
09:07AM  Sage Therapeutics Stock Up on SAGE-547 Regulatory Update
09:00AM  Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study
08:55AM  Theravance Stock Up on Fast Track Status for Velusetrag
Dec-06-16 10:21AM  5 Best Small-Cap Stocks for 2017
08:24AM  GW Pharma (GWPH) Posts Narrower-than-Expected Q4 Loss
Dec-05-16 03:21PM  Is Sucampo Pharmaceuticals, Inc. (SCMP) A Good Stock To Buy? at Insider Monkey
Dec-01-16 10:23AM  Heat Biologics Stock Falls on Negative Bladder Cancer Data
08:25AM  Achaogen (AKAO) Catches Eye: Stock Adds 6.5% in Session
Nov-30-16 05:22PM  Cytori Scleroderma Study Two-Year Follow-Up Data Published -5.25%
09:53AM  PhaseRx Soars on Orphan Drug Status for Rare Liver Disease
09:30AM  Zacks.com featured highlights: Chimera Investment, PennyMac Financial Services and Sucampo Pharmaceuticals
08:35AM  Sucampo (SCMP) Worth a Look: Stock Jumps 6.2% in Session
Nov-29-16 10:47AM  The Pockets of Speculative Action Have Dried Up +6.19%
08:25AM  Recro Pharma (REPH) in Focus: Stock Moves 19.8% Higher
Nov-28-16 03:12PM  Stocks Stay Red As Gold, Oil Prices Rise; Amazon, Building Stocks Weigh
12:15PM  Trump-Tied Plays Dip; Under Armour Up On Ticker Switch
05:01AM  How the founders of BET, Sucampo are changing the investment game for women-led companies at bizjournals.com
Nov-25-16 04:45PM  What You Need To Know For Your Week: Top 3 Earnings On Tap
01:11PM  Stocks End Thanksgiving Week With Modest Gains; Oil Slumps 3%
08:40AM  Looking for a Growth Stock? Why it is Time to Focus on Sucampo Pharmaceuticals (SCMP)
Nov-24-16 08:11AM  Glaxo Nucala Favorable in Rare Vasculitis Disease Study
Nov-23-16 08:30AM  Why Sucampo Pharmaceuticals (SCMP) Could Be Positioned for a Surge
08:18AM  Oragenics Jumps on Fast Track Status for Oral Mucositis Drug
07:38AM  Bristol-Myers' Opdivo Gets EU Approval for Label Expansion
Nov-22-16 09:30AM  Zacks.com featured highlights: Lancaster Colony, Sucampo Pharmaceuticals, VMware and Alexandria Real Estate Equities
Nov-21-16 09:27AM  4 Stocks to Buy on Solid Earnings Acceleration
Nov-18-16 11:04AM  Sucampo Pharmaceuticals, Inc. :SCMP-US: Earnings Analysis: Q3, 2016 By the Numbers : November 18, 2016
Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research and development of proprietary drugs for the treatment of gastrointestinal, ophthalmic, autoimmune, and oncology-based inflammatory disorders in the United States, Japan, Switzerland, and internationally. The company's marketed product includes AMITIZA, a ClC-2 chloride channel activator for the treatment of chronic idiopathic constipation in adults; irritable bowel syndrome with constipation in adult women; opioid-induced constipation in patients with chronic non-cancer pain; chronic constipation; and pediatric functional constipation. Its product candidates, which are in clinical development stage comprise Cobiprostone that is in Phase IIa trials for the treatment of oral mucositis, non-erosive reflux, and symptomatic gastroesophageal reflux diseases; RTU-1096, which has completed Phase I trial for treating inflammation/immune-related disorders; and RTU-009 that is in development stage for inflammation/immune-related disorders, as well as CPP-1X/sulindac combination product, which is in phase III clinical trial for the treatment of familial adenomatous polyposis. Sucampo Pharmaceuticals, Inc. was founded in 1996 is headquartered in Rockville, Maryland. Sucampo Pharmaceuticals, Inc. is a subsidiary of S&R Technology Holdings, LLC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Getman Daniel PDirectorNov 29Option Exercise6.803,79925,8333,799Nov 30 04:01 PM
Greenleaf PeterCEONov 29Option Exercise6.7582,459556,59884,972Nov 30 04:01 PM
Greenleaf PeterCEONov 29Sale16.7582,4591,381,1882,513Nov 30 04:01 PM
Getman Daniel PDirectorNov 29Sale16.753,79963,6330Nov 30 04:01 PM
Getman Daniel PDirectorNov 28Option Exercise6.8016,201110,16716,201Nov 30 04:01 PM
Greenleaf PeterCEONov 28Option Exercise6.75117,541793,402120,054Nov 30 04:01 PM
Alder MatthiasEVP, Bus. Dev.&Lic, G.C. &Sec.Nov 28Option Exercise8.3324,975208,04228,424Nov 28 09:30 PM
Alder MatthiasEVP, Bus. Dev.&Lic, G.C. &Sec.Nov 28Sale16.7324,975417,8323,449Nov 28 09:30 PM
Greenleaf PeterCEONov 28Sale16.91117,5411,987,6182,513Nov 30 04:01 PM
Getman Daniel PDirectorNov 28Sale16.8916,201273,6350Nov 30 04:01 PM
Alder MatthiasEVP, Bus. Dev.&Lic, G.C. &Sec.Nov 25Option Exercise8.3399,025824,878102,474Nov 28 09:30 PM
Alder MatthiasEVP, Bus. Dev.&Lic, G.C. &Sec.Nov 25Sale15.8899,0251,572,5173,449Nov 28 09:30 PM
Alder MatthiasEVP, Bus. Dev.&Lic, G.C. &Sec.Nov 23Option Exercise8.3326,000216,58029,449Nov 28 09:30 PM
Alder MatthiasEVP, Bus. Dev.&Lic, G.C. &Sec.Nov 23Sale15.7726,000410,0203,449Nov 28 09:30 PM
Smith Andrew PChief Financial OfficerNov 15Sale15.581,76627,514348Nov 16 04:01 PM